ABSTRACT
This study analyzes mpox cases in Burundi from July to September 2024, following the introduction of Clade Ib. During this time, 25.4% of 607 samples tested positive via PCR. Children under 15 comprised 55.2% of cases, with a higher proportion of female children testing positive. Geographic analysis demonstrates case concentration in Bujumbura Mairie (59.1%). These findings highlight the importance of age- and sex-specific interventions for outbreak containment and the need for targeted public health strategies in Burundi.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the work presented was provided by the International Mpox Research Consortium 188 (IMReC) through funding from the Canadian Institutes of Health Research and International 189 Development Research Centre (grant no. MRR-184813).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data was provided by country-wide mpox surveillance program. Permission to use this data was granted by the Institutional Ethics Committee at the Faculty of Medicine, University of Burundi (CIEB-FMCHUK no. 02/09/2024).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
